Insert title here
    登录 | 注册 | 期刊登录 | 收藏
Investigational New Drugs 2006, Vol. 24 (3 ) :233 -240 doi:10.1007/s10637-005-3690-6 <<-上一篇 下一篇 ->>
Phase I trial of oral talactoferrin alfa in refractory solid tumors
Teresa G. Hayes(12)   Gerald F. Falchook(1)   Gauri R. Varadhachary(1)   Dori P. Smith(1)   Lisa D. Davis(1)   Hari M. Dhingra(1)   Benjamin P. Hayes(1)   Atul Varadhachary(1)   
1.Michael E. DeBakey VA Medical Center and Baylor College of Medicine Houston Texas USA
2.VA 111H, Michael E. DeBakey VA Medical Center 2002 Holcombe Blvd. Houston TX 77030 USA
Abstract: Background: Lactoferrin is an iron-binding glycoprotein first identified in breast milk as a protein product of mammary epithelial cells. Its immunomodulatory functions include activation of NK and lymphokine-activated killer cells and enhancement of PMN and macrophage cytotoxicity. Studies in animal models have shown promising anti-cancer activity. The purpose of the present study was to evaluate the safety and tolerability of talactoferrin alfa (talactoferrin; TLF) in humans, as well as pharmacokinetics and pharmacodynamics. Methods: Ten adult patients with progressive advanced solid tumors who had failed conventional chemotherapy were administered oral TLF at doses from 1.5 to 9 g/day, using a 2 weeks on, 2 weeks off schedule. Patients were evaluated for drug toxicity, tumor growth rate, talactoferrin pharmacokinetics and cytokine markers. Results: Talactoferrin was very well tolerated. No hematological, hepatic, or renal toxicities were reported. A single patient had Grade 2 diarrhea, and there were no Grade 3 or 4 toxicities. Following oral administration, significant levels of talactoferrin were undetectable in circulation, but a statistically significant increase in circulating IL-18, a pharmacodynamic indicator of talactoferrin activity, was observed. Of the eight patients who were radiologically evaluable, five (63%) had stable disease by RECIST criteria two months after start of therapy, including one patient with a minor response. Seven patients (88%) had a decrease in their tumor growth rate. The three patients with non-small cell lung cancer (NSCLC) all survived for at least one year following the start of talactoferrin monotherapy. Conclusions: Talactoferrin is a promising, well-tolerated new agent that should be evaluated further in patients with refractory metastatic cancer.
Insert title here
更多服务: 作者自存档 | 投稿导航 | 全球期刊检索 | 查找审稿人
关于我们 | 隐私申明 | 免责声明 | 意见反馈 | 合作服务
Magsci ©  版权所有
Copyright © 2010 - 2013 Magtech. All Rights Reserved.